I was diagnosed with multiple sclerosis in September 2024. MS is a chronic, progressive disease of the central nervous system ...

Ocrevus appears to be a safe and effective treatment for children and adolescents with MS, according to real-world data from ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

neuro.umcg.nl Background The onset of secondary progression is a pivotal event in the course of relapsing–remitting (RR) multiple sclerosis (MS). Patients with secondary progressive MS (SPMS) ...

The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small ...

with regards to relapsing-onset and progressive-onset MS. Epidemiological investigation of multiple sclerosis (EIMS) and genes and environment in multiple sclerosis (GEMS) are population-based, ...

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...

Early diagnosis and treatment aim to minimise the impact of multiple sclerosis on their daily lives and extend their ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...